Zydus Lifesciences announced that its subsidiary, German Remedies Pharmaceuticals Private Limited (GRPPL), has received a favorable outcome regarding a tax dispute. The appellate authority has dropped an entire Rs. 1.66 million penalty originally imposed for the financial year 2018-19. The company has confirmed that this decision will have no material impact on its financial position, operations, or overall business activities.
Favorable Resolution in Tax Appeal
Following an appeal filed by German Remedies Pharmaceuticals Private Limited (GRPPL), a wholly owned subsidiary of Zydus Healthcare Limited, the Office of Commissioner, Central GST, has officially set aside the penalty demand. The original order, which involved a penalty of Rs. 1.66 million related to the alleged excess availment of Input Tax Credit during the 2018-19 financial year, has been successfully contested.
Impact on Business Operations
The company received the formal Appeal Order on April 15, 2026. Upon thorough evaluation of the ruling, Zydus Lifesciences has determined that the dropping of the penalty carries no material financial impact on the company or its subsidiary. Business operations and ongoing activities remain unaffected by this development, providing clarity to stakeholders regarding the resolution of this specific tax liability.
Source: BSE
